+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Tofacitinib Citrate Extended-Release Tablets Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
Tofacitinib Citrate Extended-Release Tablets Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030- Product Image
New

Tofacitinib Citrate Extended-Release Tablets Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • PDF Icon

    Report

  • 187 Pages
  • May 2025
  • Region: Global, United States
  • 360iResearch™
  • ID: 6082105
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
Tofacitinib citrate extended-release tablets have emerged as a pivotal treatment in managing chronic inflammatory disorders, offering enhanced patient adherence through once-daily dosing. As rheumatologists and gastroenterologists increasingly seek innovative therapies to improve long-term outcomes for individuals with rheumatoid arthritis, psoriatic arthritis and ulcerative colitis, this formulation addresses both efficacy and convenience. The landscape for extended-release delivery is shaped by ongoing developments in pharmacokinetics, patient stratification and cost containment strategies. Consequently, stakeholders across manufacturing, distribution and clinical practice are recalibrating strategies to align with evolving regulatory standards and payer expectations.

This executive summary provides a concise yet comprehensive overview of current market dynamics, regulatory influences and strategic imperatives. It highlights transformative shifts in prescribing patterns, assesses the impact of 2025 tariff adjustments in the United States and explores critical segmentation and regional nuances. Furthermore, it examines leading biopharma and contract development partners driving innovation, before presenting actionable recommendations for decision-makers. By distilling complex data into clear insights, this summary equips industry leaders with the knowledge needed to navigate the competitive landscape of extended-release tofacitinib citrate therapies.

Transformative Shifts Influencing Competitive Dynamics

Innovations in formulation science and a growing emphasis on patient-centric care have triggered transformative shifts in the tofacitinib extended-release market. Improved sustained-release matrices and advanced polymer technologies have enhanced drug stability and bioavailability, enabling predictable pharmacokinetic profiles that reduce peak-to-trough fluctuations. At the same time, digital adherence tools and telehealth platforms are facilitating remote monitoring of therapy, reinforcing once-daily dosing benefits and fostering stronger patient engagement.

Prescribing behaviors are also adapting. Clinicians are progressively favoring extended-release versions over immediate-release formulations to mitigate gastrointestinal side effects and simplify regimen complexity. Payers, in turn, are recognizing cost-benefits associated with reduced hospitalizations and fewer dose modifications. These converging trends have accelerated formulary inclusion and stimulated value-based contracting. As the market continues to mature, stakeholders must anticipate further technological advancements-such as gastro-retentive delivery systems-and shifting reimbursement frameworks that will redefine competitive positioning.

Assessing the 2025 U.S. Tariff Adjustments Impact

The U.S. trade policy adjustments slated for 2025 introduce significant considerations for the extended-release tofacitinib supply chain. Tariff escalations on active pharmaceutical ingredients and polymer excipients have the potential to amplify raw material costs, particularly for manufacturers relying on overseas sourcing. In response, several producers have begun diversifying procurement channels and exploring near-shoring arrangements to mitigate exposure to duty hikes.

Furthermore, anticipated tariff reclassifications may incentivize onshore production of formulation intermediates, prompting increased capital investment in domestic manufacturing capacity. These strategic moves can yield longer-term benefits by reducing lead times and enhancing supply chain resilience. Nevertheless, during the transition, stakeholders must proactively adjust pricing models and contractual clauses to reflect altered input costs. By employing comprehensive scenario planning and cross-functional collaboration, organizations can navigate the tariff landscape and safeguard margins without compromising product accessibility.

Comprehensive Segmentation Driving Market Strategy

A nuanced segmentation framework reveals distinct drivers of demand across patient profiles, care settings, product attributes and therapeutic indications. When analyzing patient demographics, the market encompasses adult, geriatric, middle-aged and pediatric populations, with further differentiation among African American, Asian, Caucasian and Hispanic and Latino cohorts, alongside gender-specific considerations. Each subgroup exhibits unique tolerability patterns and adherence challenges, informing tailored patient support programs.

In terms of end-user application, utilization spans hospital pharmacies engaged in inpatient and outpatient infusion services, online pharmacies leveraging mail-order convenience, research and academic institutions focused on clinical trials and formulary evaluations, and retail pharmacies serving local community needs. Discerning the purchasing behavior of each channel can optimize distribution strategies and contract negotiations.

The formulation and dosage segmentation underscores variations between combination formulations-both fixed-dose combinations and free combination therapy-and standalone dosage strengths categorized as high, moderate and low dose. This delineation enables precise alignment with prescribing guidelines and facilitates portfolio optimization.

Finally, disease condition segmentation examines psoriatic arthritis presentations with and without plaque psoriasis, rheumatoid arthritis classified as moderate or severe, and ulcerative colitis stratified by mild, moderate and severe disease activity. Understanding prevalence shifts and therapeutic response rates within each indication supports targeted marketing and clinical development efforts.

Regional Variations Shaping Growth Trajectories

Regional dynamics play a determining role in the adoption of extended-release tofacitinib formulations. In the Americas, well-established regulatory pathways and robust payer infrastructures accelerate reimbursement approvals, while patient advocacy groups drive awareness campaigns focused on long-term disease management. Conversely, the Europe, Middle East & Africa region presents a heterogeneous landscape: certain European markets have established reference pricing and cost-effectiveness thresholds, whereas emerging Middle Eastern and African countries are prioritizing capacity building in specialty care,
creating opportunities for public-private partnerships. In the Asia-Pacific, rapid urbanization, expanding hospital networks and government initiatives to improve healthcare access are fueling demand. Nevertheless, local manufacturing mandates and pricing controls necessitate flexible commercialization models adapted to each national context.

Key Industry Players and Competitive Landscape

A diverse array of pharmaceutical and contract development organizations contributes to the extended-release tofacitinib ecosystem. Specialty drug developers such as Pfizer Inc. and Sun Pharmaceutical Industries Ltd. leverage proprietary formulation expertise, while generics manufacturers including Teva Pharmaceutical Industries Ltd. and Dr. Reddy’s Laboratories Ltd. capitalize on cost-effective scale production. Contract development and manufacturing partners like Catalent, Inc. and Aurobindo Pharma USA, Inc. offer integrated services spanning formulation development to commercial manufacturing, facilitating market entry for new or niche players.

Similarly, biosimilar and small-molecule specialists such as Biocon Limited and Sandoz Inc. (a Novartis division) are expanding their extended-release portfolios, reflecting growing competition. Companies like Amneal Pharmaceuticals, Inc., Lupin Pharmaceuticals, Inc. and Zydus Pharmaceuticals (USA) Inc. are strategically enhancing their downstream distribution networks to capture incremental market share. Meanwhile, mid-scale innovators such as Glenmark Pharmaceuticals Ltd., Hetero Labs Limited and Cipla USA Inc. are investing in process optimization to reduce production cycles and improve cost per unit. Collectively, this landscape underscores the importance of strategic alliances, capacity expansion and differentiation through novel technologies.

Actionable Recommendations for Market Leaders

To thrive in a rapidly evolving market, industry leaders should pursue several strategic imperatives. First, invest in advanced formulation research to develop next-generation gastro-retentive or targeted release systems that further improve patient outcomes. Second, establish diversified supply agreements and near-shore production to reduce tariff exposure and enhance supply chain agility. Third, leverage real-world evidence and health economic data to support value-based contracting negotiations with payers and integrated delivery networks. Fourth, tailor patient support programs by demographic and indication segment to boost adherence and reinforce brand loyalty. Fifth, explore strategic partnerships or acquisitions with contract development organizations to accelerate time-to-market and expand manufacturing capacity. Finally, adopt region-specific market models, combining direct sales in well-reimbursed markets with distribution alliances and public sector collaborations in emerging economies, to maximize global reach.

Conclusion

In summary, the extended-release tofacitinib citrate segment presents compelling opportunities for stakeholders who embrace innovation, strategic collaboration and data-driven decision-making. Continued advancements in drug delivery technology, coupled with targeted segmentation and adaptive regional strategies, will underpin competitive advantage. Simultaneously, proactive management of tariff impacts and patient-centric initiatives will safeguard profitability and support sustainable growth. By integrating these insights into corporate planning, organizations can position themselves at the forefront of a dynamic therapeutic category, delivering improved patient outcomes while meeting evolving commercial and regulatory demands.

Market Segmentation & Coverage

This research report categorizes the Tofacitinib Citrate Extended-Release Tablets Market to forecast the revenues and analyze trends in each of the following sub-segmentations:

  • Age Group
    • Adult
    • Geriatric
    • Middle-Aged
    • Pediatric
  • Ethnicity
    • African American
    • Asian
    • Caucasian
    • Hispanic and Latino
  • Gender
    • Female
    • Male
  • Hospital Pharmacies
  • Online Pharmacies
  • Research and Academic Institutions
  • Retail Pharmacies
  • Combination Formulations
    • Fixed-Dose Combinations
    • Free Combination Therapy
  • Dosage Strength
    • High Dose
    • Low Dose
    • Moderate Dose
  • Psoriatic Arthritis
    • With Plaque Psoriasis
    • Without Plaque Psoriasis
  • Rheumatoid Arthritis
    • Moderate RA
    • Severe RA
  • Ulcerative Colitis
    • Mild UC
    • Moderate UC
    • Severe UC

This research report categorizes the Tofacitinib Citrate Extended-Release Tablets Market to forecast the revenues and analyze trends in each of the following sub-regions:

  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam
  • Europe, Middle East & Africa
    • Denmark
    • Egypt
    • Finland
    • France
    • Germany
    • Israel
    • Italy
    • Netherlands
    • Nigeria
    • Norway
    • Poland
    • Qatar
    • Russia
    • Saudi Arabia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Turkey
    • United Arab Emirates
    • United Kingdom

This research report categorizes the Tofacitinib Citrate Extended-Release Tablets Market to delves into recent significant developments and analyze trends in each of the following companies:

  • Alembic Pharmaceuticals Limited
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Aurobindo Pharma USA, Inc.
  • Biocon Limited
  • Catalent, Inc.
  • Cipla USA Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Labs Limited
  • Lupin Pharmaceuticals, Inc.
  • Mylan N.V. (now part of Viatris Inc.)
  • Pfizer Inc.
  • Sandoz Inc. (a Novartis Division)
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Pharmaceuticals (USA) Inc. (a part of Cadila Healthcare)

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Tofacitinib Citrate Extended-Release Tablets Market, by Patient Demographics
8.1. Introduction
8.2. Age Group
8.2.1. Adult
8.2.2. Geriatric
8.2.3. Middle-Aged
8.2.4. Pediatric
8.3. Ethnicity
8.3.1. African American
8.3.2. Asian
8.3.3. Caucasian
8.3.4. Hispanic and Latino
8.4. Gender
8.4.1. Female
8.4.2. Male
9. Tofacitinib Citrate Extended-Release Tablets Market, by End-User Application
9.1. Introduction
9.2. Hospital Pharmacies
9.3. Online Pharmacies
9.4. Research and Academic Institutions
9.5. Retail Pharmacies
10. Tofacitinib Citrate Extended-Release Tablets Market, by Formulation and Dosage
10.1. Introduction
10.2. Combination Formulations
10.2.1. Fixed-Dose Combinations
10.2.2. Free Combination Therapy
10.3. Dosage Strength
10.3.1. High Dose
10.3.2. Low Dose
10.3.3. Moderate Dose
11. Tofacitinib Citrate Extended-Release Tablets Market, by Disease Condition
11.1. Introduction
11.2. Psoriatic Arthritis
11.2.1. With Plaque Psoriasis
11.2.2. Without Plaque Psoriasis
11.3. Rheumatoid Arthritis
11.3.1. Moderate RA
11.3.2. Severe RA
11.4. Ulcerative Colitis
11.4.1. Mild UC
11.4.2. Moderate UC
11.4.3. Severe UC
12. Americas Tofacitinib Citrate Extended-Release Tablets Market
12.1. Introduction
12.2. Argentina
12.3. Brazil
12.4. Canada
12.5. Mexico
12.6. United States
13. Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Market
13.1. Introduction
13.2. Australia
13.3. China
13.4. India
13.5. Indonesia
13.6. Japan
13.7. Malaysia
13.8. Philippines
13.9. Singapore
13.10. South Korea
13.11. Taiwan
13.12. Thailand
13.13. Vietnam
14. Europe, Middle East & Africa Tofacitinib Citrate Extended-Release Tablets Market
14.1. Introduction
14.2. Denmark
14.3. Egypt
14.4. Finland
14.5. France
14.6. Germany
14.7. Israel
14.8. Italy
14.9. Netherlands
14.10. Nigeria
14.11. Norway
14.12. Poland
14.13. Qatar
14.14. Russia
14.15. Saudi Arabia
14.16. South Africa
14.17. Spain
14.18. Sweden
14.19. Switzerland
14.20. Turkey
14.21. United Arab Emirates
14.22. United Kingdom
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Alembic Pharmaceuticals Limited
15.3.2. Amneal Pharmaceuticals, Inc.
15.3.3. Apotex Inc.
15.3.4. Aurobindo Pharma USA, Inc.
15.3.5. Biocon Limited
15.3.6. Catalent, Inc.
15.3.7. Cipla USA Inc.
15.3.8. Dr. Reddy's Laboratories Ltd.
15.3.9. Glenmark Pharmaceuticals Ltd.
15.3.10. Hetero Labs Limited
15.3.11. Lupin Pharmaceuticals, Inc.
15.3.12. Mylan N.V. (now part of Viatris Inc.)
15.3.13. Pfizer Inc.
15.3.14. Sandoz Inc. (a Novartis Division)
15.3.15. Strides Pharma Science Limited
15.3.16. Sun Pharmaceutical Industries Ltd.
15.3.17. Teva Pharmaceutical Industries Ltd.
15.3.18. Torrent Pharmaceuticals Ltd.
15.3.19. Zydus Pharmaceuticals (USA) Inc. (a part of Cadila Healthcare)
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET MULTI-CURRENCY
FIGURE 2. TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET MULTI-LANGUAGE
FIGURE 3. TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET RESEARCH PROCESS
FIGURE 4. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 5. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2030 (%)
FIGURE 8. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2024 VS 2030 (%)
FIGURE 10. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2024 VS 2030 (%)
FIGURE 12. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2024 VS 2030 (%)
FIGURE 14. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET, FPNV POSITIONING MATRIX, 2024
List of Tables
TABLE 1. TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 7. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ADULT, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY MIDDLE-AGED, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AFRICAN AMERICAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ASIAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY CAUCASIAN, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HISPANIC AND LATINO, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FEMALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY MALE, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RESEARCH AND ACADEMIC INSTITUTIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FIXED-DOSE COMBINATIONS, BY REGION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FREE COMBINATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY HIGH DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY LOW DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY MODERATE DOSE, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY WITH PLAQUE PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY WITHOUT PLAQUE PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY MODERATE RA, BY REGION, 2018-2030 (USD MILLION)
TABLE 45. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SEVERE RA, BY REGION, 2018-2030 (USD MILLION)
TABLE 46. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 47. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 48. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY MILD UC, BY REGION, 2018-2030 (USD MILLION)
TABLE 49. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY MODERATE UC, BY REGION, 2018-2030 (USD MILLION)
TABLE 50. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY SEVERE UC, BY REGION, 2018-2030 (USD MILLION)
TABLE 51. GLOBAL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 52. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 53. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 54. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 55. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 56. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 57. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 58. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 59. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 60. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 61. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 62. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 63. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 64. AMERICAS TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 65. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 66. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 67. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 68. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 69. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 70. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 71. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 72. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 73. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 74. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 75. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 76. ARGENTINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 77. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 78. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 79. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 80. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 81. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 82. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 83. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 84. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 85. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 86. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 87. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 88. BRAZIL TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 89. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 90. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 91. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 92. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 93. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 94. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 95. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 96. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 97. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 98. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 99. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 100. CANADA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 101. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 102. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 103. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 104. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 105. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 106. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 107. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 108. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 109. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 110. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 111. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 112. MEXICO TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 113. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 114. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 115. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 116. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 117. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 118. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 119. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 120. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 121. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 122. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 123. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 124. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 125. UNITED STATES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 126. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 127. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 128. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 129. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 130. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 131. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 132. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 133. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 134. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 135. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 136. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 137. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 138. ASIA-PACIFIC TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 139. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 140. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 141. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 142. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 143. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 144. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 145. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 146. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 147. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 148. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 149. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 150. AUSTRALIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 151. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 152. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 153. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 154. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 155. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 156. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 157. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 158. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 159. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 160. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 161. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 162. CHINA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 163. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 164. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 165. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 166. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 167. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 168. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 169. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 170. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 171. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 172. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 173. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 174. INDIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 175. INDONESIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 176. INDONESIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 177. INDONESIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 178. INDONESIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 179. INDONESIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 180. INDONESIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 181. INDONESIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 182. INDONESIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 183. INDONESIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 184. INDONESIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 185. INDONESIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 186. INDONESIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 187. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 188. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 189. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 190. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 191. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 192. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 193. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 194. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 195. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 196. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 197. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 198. JAPAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 199. MALAYSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 200. MALAYSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 201. MALAYSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 202. MALAYSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 203. MALAYSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 204. MALAYSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 205. MALAYSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 206. MALAYSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 207. MALAYSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 208. MALAYSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 209. MALAYSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 210. MALAYSIA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 211. PHILIPPINES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 212. PHILIPPINES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 213. PHILIPPINES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 214. PHILIPPINES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 215. PHILIPPINES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 216. PHILIPPINES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 217. PHILIPPINES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 218. PHILIPPINES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 219. PHILIPPINES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 220. PHILIPPINES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 221. PHILIPPINES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 222. PHILIPPINES TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 223. SINGAPORE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 224. SINGAPORE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 225. SINGAPORE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 226. SINGAPORE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 227. SINGAPORE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 228. SINGAPORE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 229. SINGAPORE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 230. SINGAPORE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 231. SINGAPORE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 232. SINGAPORE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 233. SINGAPORE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 234. SINGAPORE TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 235. SOUTH KOREA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 236. SOUTH KOREA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 237. SOUTH KOREA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 238. SOUTH KOREA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 239. SOUTH KOREA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 240. SOUTH KOREA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 241. SOUTH KOREA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 242. SOUTH KOREA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 243. SOUTH KOREA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 244. SOUTH KOREA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 245. SOUTH KOREA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 246. SOUTH KOREA TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 247. TAIWAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 248. TAIWAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 249. TAIWAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 250. TAIWAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 251. TAIWAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 252. TAIWAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 253. TAIWAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 254. TAIWAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STRENGTH, 2018-2030 (USD MILLION)
TABLE 255. TAIWAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DISEASE CONDITION, 2018-2030 (USD MILLION)
TABLE 256. TAIWAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PSORIATIC ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 257. TAIWAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY RHEUMATOID ARTHRITIS, 2018-2030 (USD MILLION)
TABLE 258. TAIWAN TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ULCERATIVE COLITIS, 2018-2030 (USD MILLION)
TABLE 259. THAILAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY PATIENT DEMOGRAPHICS, 2018-2030 (USD MILLION)
TABLE 260. THAILAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
TABLE 261. THAILAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY ETHNICITY, 2018-2030 (USD MILLION)
TABLE 262. THAILAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY GENDER, 2018-2030 (USD MILLION)
TABLE 263. THAILAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY END-USER APPLICATION, 2018-2030 (USD MILLION)
TABLE 264. THAILAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY FORMULATION AND DOSAGE, 2018-2030 (USD MILLION)
TABLE 265. THAILAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY COMBINATION FORMULATIONS, 2018-2030 (USD MILLION)
TABLE 266. THAILAND TOFACITINIB CITRATE EXTENDED-RELEASE TABLETS MARKET SIZE, BY DOSAGE STR

Companies Mentioned

  • Alembic Pharmaceuticals Limited
  • Amneal Pharmaceuticals, Inc.
  • Apotex Inc.
  • Aurobindo Pharma USA, Inc.
  • Biocon Limited
  • Catalent, Inc.
  • Cipla USA Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.
  • Hetero Labs Limited
  • Lupin Pharmaceuticals, Inc.
  • Mylan N.V. (now part of Viatris Inc.)
  • Pfizer Inc.
  • Sandoz Inc. (a Novartis Division)
  • Strides Pharma Science Limited
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Torrent Pharmaceuticals Ltd.
  • Zydus Pharmaceuticals (USA) Inc. (a part of Cadila Healthcare)

Methodology

Loading
LOADING...

Related Topics

Related Reports

Janus Kinase (JAK) Inhibitors Market Report 2025 - Product Image

Janus Kinase (JAK) Inhibitors Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Tofacitinib Market Report 2025 - Product Image

Tofacitinib Market Report 2025

  • Report
  • 200 Pages
  • Global
From
Bismuth Potassium Citrate Oral Solution Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030 - Product Image

Bismuth Potassium Citrate Oral Solution Market - Cumulative Impact of United States Tariffs 2025 - Global Forecast to 2030

  • Report
  • 192 Pages
  • Global, United States Global, United States
From
Potassium Citrate Market Report by Type, Function, End User, and Region 2025-2033 - Product Image

Potassium Citrate Market Report by Type, Function, End User, and Region 2025-2033

  • Report
  • 145 Pages
  • Global
From
Ulcerative Colitis - Market Insight, Epidemiology, and Market Forecast - 2034 - Product Image

Ulcerative Colitis - Market Insight, Epidemiology, and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.